There may be some serious problems.
VRX changed its CEP and promised to lower its drug prices significantly. Other price gougers should do the same before become another VRX.
$25B at 6% interest rate is $1.5B and STJ income is not enough for ABT interest payment.
Of course, ABT pays 45% of it by diluting its shares but still pays about $14B with borrowed money.
$14b at 6% is $840m per year. This is almost equal to STJ income per year. But how about 250m shares that ABT dilutes and its effect of ABT income. Short term, ABT will not see any benefit and probably some reduced income.
It may not have those kind of growth that some analysts want based on peers but it still growing.
After all, current prices are good for a stock it does not grow while TWTR is growing in double digit.
Following are revenue since TWTR went public:
Q3-2013 *** $168m
Q4-2013 *** $242m
Q1-2014 *** $250m
Q2-2014 *** $312m
Q3-2014 *** $361m
Q4-2014 *** $479m
Q1-2015 *** $436m
Q2-2015 *** $502m
Q3-2015 *** $569m
Q4-2015 *** $710m
Q1-2016 *** $595m
Q1-2014 was also was low when it is compared to the previous quarter.
Bottom line, TWTR is growing. FB was doing the same in early years. FB went down to $20 but eventually found its way up.
Some companies go down after an acquisition, especially if the deal is not accretive immediately. HZNP went down after acquisition of krystexxa. Last week, BRCM went down over 10% after an acquisition announcement.
IRWD stock is not the point but the drug Zurampic is the point. Zurampic will compete with krystexxa or actually kills ultra expensive krystexxa. TW wasted $510m cash and paid himself another $100m.
AstraZeneca plans to seek further approval of Zurampic in combination with a generic gout drug called allopurinol later this year, and under the deal, Ironwood would also have exclusive rights to that drug if approved.
Was TW blind or what!? I think, he got DEPO effect while he could not think clearly or he did but there was something else.
RKUS revenue in past 4 years is showing sizable growth year over year
2012 ** $214 m
2013 ** $263 m
2014 ** $327 m
2015 ** $373 m
And the current estimate for 2016 and 2017 are:
2016 ** 430 m
2017 ** 488 m
This is an amazing growth for BRCD and RKUS worth every penny paid for it.
Sentiment: Strong Buy
You never know when this will happen but some people are profiting on expense of naïve retails.
There is no risk for these guys. They loaded at low and now they are pumping. A few million dollars in a few days is not a bad deal. They will dump eventually and retails will be losers again.
There is a lot of risk in this stock.
After HZNP offer I do not think anyone dare to get close to DEPO.
DEPO will play between $10 to $14. If it drops below $10 then it will be a good play.